Published in J Neurosci on June 01, 2000
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
Pathways towards and away from Alzheimer's disease. Nature (2004) 8.72
AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron (2006) 6.76
Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A (2004) 5.65
Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A (2002) 5.46
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A (2003) 5.44
Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci (2010) 5.03
Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A (2003) 4.80
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med (2009) 4.11
The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest (2008) 4.09
Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron (2009) 3.94
Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci (2009) 3.77
Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (2006) 3.74
Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron (2005) 3.72
Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One (2010) 3.62
Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 3.61
Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci (2010) 3.36
Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature (2010) 3.36
Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell (2011) 3.28
Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell (2012) 3.16
Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A (2009) 2.96
Probing the biology of Alzheimer's disease in mice. Neuron (2010) 2.96
Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci (2011) 2.96
Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A (2010) 2.86
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A (2012) 2.84
Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A (2003) 2.83
Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med (2012) 2.77
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A (2002) 2.76
Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci U S A (2002) 2.57
Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 2.56
Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A (2010) 2.45
Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci U S A (2006) 2.45
beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.40
Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science (2016) 2.35
In silico study of amyloid beta-protein folding and oligomerization. Proc Natl Acad Sci U S A (2004) 2.13
Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron (2010) 2.10
Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc Natl Acad Sci U S A (2008) 2.09
Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J (2004) 2.08
Changes in the structural complexity of the aged brain. Aging Cell (2007) 1.96
Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One (2010) 1.92
Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer's disease. Neuron (2015) 1.92
Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain (2013) 1.91
Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet (2010) 1.90
Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest (2006) 1.87
Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc Natl Acad Sci U S A (2003) 1.86
Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain (2010) 1.86
Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A (2008) 1.84
Soluble Aβ oligomer production and toxicity. J Neurochem (2011) 1.83
Alzheimer's disease. Cold Spring Harb Perspect Biol (2011) 1.81
Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci (2008) 1.78
Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener (2009) 1.73
Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am J Pathol (2004) 1.71
Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol (2001) 1.69
Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci U S A (2009) 1.69
Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease. Cell Stem Cell (2009) 1.68
Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol (2004) 1.66
Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology (2011) 1.66
Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci (2009) 1.66
Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol (2004) 1.66
Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain (2013) 1.64
Alzheimer disease. Dis Mon (2010) 1.64
Molecular dynamics simulation of amyloid beta dimer formation. Biophys J (2004) 1.63
Progranulin protects against amyloid β deposition and toxicity in Alzheimer's disease mouse models. Nat Med (2014) 1.63
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem (2011) 1.63
Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience (2007) 1.59
Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2012) 1.58
Amyloid beta-protein toxicity and the pathogenesis of Alzheimer disease. J Biol Chem (2008) 1.57
Synapses and Alzheimer's disease. Cold Spring Harb Perspect Biol (2012) 1.57
Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet (2014) 1.56
Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med (2007) 1.55
Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci (2009) 1.54
Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. J Neurosci (2011) 1.53
Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest (2002) 1.51
The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J Neurosci (2012) 1.50
DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice. Nat Commun (2015) 1.49
Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron (2008) 1.49
RAGE inhibition in microglia prevents ischemia-dependent synaptic dysfunction in an amyloid-enriched environment. J Neurosci (2014) 1.47
The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. J Biol Chem (2008) 1.46
Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest (2005) 1.45
Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci (2010) 1.44
Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest (2006) 1.43
Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther (2011) 1.43
Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol (2014) 1.43
Alzheimer's disease: synapses gone cold. Mol Neurodegener (2011) 1.43
Cross-species translation of the Morris maze for Alzheimer's disease. J Clin Invest (2016) 1.43
The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation. Neuron (2013) 1.43
Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A (2010) 1.42
Chronic Microdose Lithium Treatment Prevented Memory Loss and Neurohistopathological Changes in a Transgenic Mouse Model of Alzheimer's Disease. PLoS One (2015) 1.42
beta -Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci U S A (2001) 1.42
Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J Neurosci (2009) 1.42
CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem (2011) 1.40
Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A (2011) 1.39
Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis (2009) 1.37
Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol (2007) 1.36
Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc Natl Acad Sci U S A (2004) 1.36
Exercise improves cognition and hippocampal plasticity in APOE epsilon4 mice. Alzheimers Dement (2009) 1.36
Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology. J Neurosci (2012) 1.34
Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cytotoxicity. J Biol Chem (2008) 1.33
Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci (2008) 1.33
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature (1992) 6.51
Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science (2000) 6.28
Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature (1999) 5.77
Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A (1999) 5.75
Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A (1997) 4.92
The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron (1995) 4.78
Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem (2001) 4.45
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med (1997) 4.10
Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst (2000) 4.09
Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature (1994) 3.87
TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med (2001) 3.84
The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology (1990) 3.79
Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1993) 3.73
Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol (1997) 3.38
Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology (2001) 3.30
A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature (2001) 3.28
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Molecular cloning and expression of the mouse ornithine decarboxylase gene. Proc Natl Acad Sci U S A (1984) 2.83
Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A (1993) 2.79
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol (1998) 2.77
BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet (2001) 2.76
Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci (1996) 2.69
Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol (1995) 2.62
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology (2002) 2.47
beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.40
Distribution of brain HIV load in AIDS. Brain Pathol (1998) 2.36
alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol (2000) 2.36
Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem (1997) 2.33
Diffuse plaques do not accentuate synapse loss in Alzheimer's disease. Am J Pathol (1990) 2.24
Transcription of the hypersensitive site HS2 enhancer in erythroid cells. Proc Natl Acad Sci U S A (1992) 2.20
Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol (1998) 2.19
Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab (2010) 2.16
Neocortical damage during HIV infection. Ann Neurol (1991) 2.15
beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron (2001) 2.05
Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J Neurosci Res (2001) 2.04
Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature (1997) 1.99
Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J Biol Chem (1995) 1.95
Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol (1994) 1.90
Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation (1999) 1.89
Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol (1999) 1.89
Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 1.87
The National NeuroAIDS Tissue Consortium: a new paradigm in brain banking with an emphasis on infectious disease. Neuropathol Appl Neurobiol (2001) 1.86
Actin filament polymerization regulates gliding motility by apicomplexan parasites. Mol Biol Cell (2003) 1.85
Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol (2003) 1.81
Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett (1994) 1.81
Analysis of result variability from high-density oligonucleotide arrays comparing same-species and cross-species hybridizations. Biotechniques (2002) 1.80
Neuronal death and perinatal lethality in voltage-gated sodium channel alpha(II)-deficient mice. Biophys J (2000) 1.79
Overexpression of tau in a nonneuronal cell induces long cellular processes. J Cell Biol (1991) 1.77
Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol (2009) 1.75
Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann Neurol (2001) 1.75
Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology (2004) 1.74
Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med (2000) 1.71
Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol (1995) 1.66
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab (2008) 1.66
Apolipoprotein E and cognitive performance. Nature (2000) 1.64
Quantitative synaptic alterations in the human neocortex during normal aging. Neurology (1993) 1.61
Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology (1997) 1.58
Cholinergic dysfunction in diseases with Lewy bodies. Neurology (2000) 1.58
Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Brain Res (1994) 1.58
Identification and nucleotide sequence of the activator gene of the externally induced phosphoglycerate transport system of Salmonella typhimurium. Gene (1986) 1.58
Neurochemical markers do not correlate with cognitive decline in the Lewy body variant of Alzheimer disease. Arch Neurol (1999) 1.56
Altered control of postural sway following cerebral infarction: a cross-sectional analysis. Neurology (2010) 1.55
Borna disease virus in human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. J Infect Dis (1999) 1.53
Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res (2008) 1.50
Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol (1996) 1.50
Overexpression of the sarcolemmal calcium pump in the myocardium of transgenic rats. Circ Res (1998) 1.49